Gilead continues its divergence out of its original infectious disease beginnings and into cancer and now, more deeply than ...
After he was found in contempt twice in one week, Rudy Giuliani faces another treacherous week ahead at a trial to determine ...
Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule ...
Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...
Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.
Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs ...
Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of ...
Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a ...
Kaken will take the drug through phase I trials, after which J&J takes over. Under the terms, Kaken banks an up-front payment of $30 million and could collect more than $1.2 billion if development and ...
Johnson & Johnson JNJ announced entering into an exclusive global licensing agreement with Kaken Pharmaceutical to develop, ...